The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease

Respiratory Research

Volumn 3, Issue , 2001, Pages

  Keane, Michael P ^a   Strieter, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemokine; Cytokine; Fibrosis; Inflammation; Lung

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR5; COLLAGEN; CX3C CHEMOKINE; CYTOKINE; GAMMA CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; CHRONIC LUNG DISEASE; COLLAGEN SYNTHESIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FIBROSING ALVEOLITIS; HUMAN; IMMUNOPATHOGENESIS; LUNG FIBROBLAST; LUNG SARCOIDOSIS; NONHUMAN; PNEUMONIA; REVIEW; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL;

EID: 25444481541     PISSN: 1465993X     EISSN: None     Source Type: Journal    
DOI: 10.1186/rr177     Document Type: Review

References (52)

1. Dinarello CA: Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann NY Acad Sci 1998, 856: 1-11.
2. Murphy JE, Robert C, Kupper TS: Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J Invest Dermatol 2000, 114:602-608.
3. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
4. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J: Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001, 107: 1529-1536.
5. Piguet P, Vesin C, Grau G, Thompson RC: Interleukin 1 receptor anatgonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993, 5:57-61.
6. Rolfe MW, Standiford TJ, Kunkel SL, Burdick MD, Gilbert AR, Moore SA, Lynch JP, Strieter RM: Interleukin-1 receptor antagonist expression in sarcoidosis. Am Rev Respir Dis 1993, 148: 1378-1384.
7. Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch JP 3rd, Arenberg DA, Wilke CA, Burdick MD, Martinez FJ, Hampton JN, Whyte RI, Orringer MB, Strieter RM: Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis. Am J Respir Crit Care Med 1995, 151:1965-1973.
8. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334:1717-1725.
9. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N: Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999, 104:13-19.
10. Genersch E, Hayess K, Neuenfeld Y, Haller H: Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J Cell Sci 2000, 113:4319-4330.
11. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor necrosis factor/cachectin plays a key role in bleomycininduced pneumopathy. J Exp Med 1989, 170 :655-663.
12. Piguet PF, Vesin C: Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silca in mice. Eur Respir J 1994, 7:515-518.
13. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, Gauldie J: Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factorbeta1 and myofibroblasts. Am J Pathol 1998, 153:825-832.
14. Romagnani S: Th1/Th2 cells. Inflamm Bowel Dis 1999, 5:285-294.
15. Duncan MR, Berman B: Differential regulation of collagen, glycosaminoglycan, fibronectin, and collagenase activity production in cultured human adult dermal fibroblasts by interleukin-1-alpha and beta and tumornecrosis factor-alpha and beta. J Invest Dermatol 1989, 92:699-706.
16. Giri SN, Hyde DM, Marafino BJ: Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice. Biochem Med Metab Biol 1986, 36:194-197.
17. Brody AR, Bonner JC, Badgett A: Recombinant interferon-gamma reduces PDGF-induced lung fibroblast growth but stimulates PDGF production by alveolar macrophages in vitro. Chest 1993, 103:121S-122S.
18. Lewis M, Amento EP, Unemori EN: Transcriptional inhibition of stromelysin by interferon-gamma in normal human fibroblasts is mediated by the AP-1 domain. J Cell Biochem 1999, 72:373-386.
19. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF: Interferon-gamma and interleukin-4 differentially regulate ICAM-1 and VCAM-1 expression on human lung fibroblasts. Eur Respir J 1999, 14:759-766.
20. Keane MP, Belperio JA, Burdick MD, Strieter RM: IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2001, 281:L92-97.
21. Hein R, Behr J, Hundgen M, Hunzelmann N, Meurer M, Braun-Falco O, Urbanski A, Krieg T: Treatment of systemic sclerosis with gamma-interferon. Br J Dermatol 1992, 126:496-501.
22. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH: A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999, 341:1264-1269.
23. Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin-4. J Clin Invest 1992, 90:1479-1485.
24. Rankin JA, Picarella DE, Geba GP, Temann UA, Prasad B, DiCosmo B, Tarallo A, Stripp B, Whitsett J, Flavell RA: Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci USA 1996, 93:7821-7825.
25. Chensue SW, Warmington K, Ruth JH, Lukacs N, Kunkel SL: Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice: analysis of local and regional cytokine and chemokine networks. J Immunol 1997, 159:3565-3573 [published erratum appears in J Immunol 1999, 162:3106].
26. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM: Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000, 292:988-994.
27. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103:779-788.
28. Mohrs M, Ledermann B, Kohler G, Dorfmuller A, Gessner A, Brombacher F: Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 1999, 162: 7302-7308.
29. Wallace WAH, Ramage EA, Lamb D, Howie EM: A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with crytogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995, 101:436-441.
30. Kuroki S, Ohta A, Sueoka N, Katoh O, Yamada H, Yamaguchi M: Determination of various cytokines and type III procollagen aminopeptide levels in bronchoalveolar lavage fluid of the patients with pulmonary fibrosis: inverse correlation between type III procollagen aminopeptide and interferon-γ in progressive fibrosis. Brit J Rheum 1995, 34:31-36.
31. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL: Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995, 155:2222-2229.
32. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ: Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995, 155:722-729.
33. Nelson DR, Lauwers GY, Lau JY, Davis GL: Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000, 118:655-660.
34. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE: Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
35. Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H, Nishino K, Osaki T, Tachibana I, Kaneda Y, Hayashi S: Introduction of the interleukin-10 gene into mice inhibited bleomycininduced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 2000, 278:L914-922.
36. Driscoll KE, Carter JM, Howard BW, Hassenbein D, Burdick M, Kunkel SL, Strieter RM: Interleukin-10 regulates quartz-induced pulmonary inflammation in rats. Am J Physiol 1998, 275:L887-894.
37. Huaux F, Lardot C, Arras M, Delos M, Many MC, Coutelier JP, Buchet JP, Renauld JC, Lison D: Lung fibrosis induced by silica particles in NMRI mice is associated with an upregulation of the p40 subunit of interleukin-12 and Th-2 manifestations. Am J Respir Cell Mol Biol 1999, 20:561-572.
38. Huaux F, Louahed J, Hudspith B, Meredith C, Delos M, Renauld JC, Lison D: Role of interleukin-10 in the lung response to silica in mice. Am J Respir Cell Mol Biol 1998, 18:51-59.
39. Arras M, Huaux F, Vink A, Delos M, Coutelier JP, Many MC, Barbarin V, Renauld JC, Lison D: Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model. Am J Respir Cell Mol Biol 2001, 24:368-375.
40. Hoyle GW, Brody AR: IL-9 and lung fibrosis: a Th2 good guy? Am J Respir Cell Mol Biol 2001, 24:365-367.
41. Lynch I, J.P., Standiford TJ, Kunkel SL, Rolfe MW, Strieter RM: Neutrophilic alveolitis in idiopathic pulmonary fibrosis: the role of interleukin-8. Am Rev Respir Dis 1992, 145:1433-1438.
42. Southcott AM, Jones KP, Li D, Majumdar S, Cambrey AD, Pantelidis P, Black CM, Laurent GJ, Davis BH, Jeffrey PK, et al.: Interleukin-8, differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 1995, 151: 1604-1612.
43. Standiford TJ, Rolfe MW, Kunkel SL, Lynch JPI, Burdick MD, Gilbert AR, Orringer MB, Whyte RI, Strieter RM: Macrophage inflammatory protein-1α expression in interstitial lung disease. J Immunol 1993, 151:2852-2863.
44. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404:407-411.
45. Orlofsky A, Wu Y, Prystowsky MB: Divergent regulation of the murine CC chemokine C10 by Th(1) and Th(2) cytokines. Cytokine 2000, 12:220-228.
46. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, Panzer U, Stahl RA, Hauser IA, Budde K, Neumayer H, Kramer BK, Land W, Schlondorff D: CC chemokine receptor 5 and renal-transplant survival. Lancet 2001, 357: 1758-1761.
47. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, Bunce M, Weigl E, Du Bois R: CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000, 162:1000-1003.
48. Turner-Warwick M: Precapillary systemic-pulmonary anastomoses. Thorax 1963, 18:225-237.
49. Peao MND, Aguas AP, DeSa CM, Grande NR: Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin. Anat Rec 1994, 238:57-67.
50. Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997, 159:1437-1443.
51. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM: Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999, 162:5511-5518.
52. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM: IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999, 163:5686-5692.